P2.01-092 PRMT5 is a Poor Prognostic Marker for NSCLC and Inhibition of PRMT5 Results in Increased Lung Cancer Sensitivity to Cisplatin and Radiotherapy

Meng Welliver; Feng Jin; Gregory Otterson; David Carbone

首页> 外文期刊>Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer >P2.01-092 PRMT5 is a Poor Prognostic Marker for NSCLC and Inhibition of PRMT5 Results in Increased Lung Cancer Sensitivity to Cisplatin and Radiotherapy

【24h】

P2.01-092 PRMT5 is a Poor Prognostic Marker for NSCLC and Inhibition of PRMT5 Results in Increased Lung Cancer Sensitivity to Cisplatin and Radiotherapy

机译：P2.01-092 PRMT5是NSCLC的较差的预后标记，抑制PRMT5导致肺癌对顺铂和放射治疗的敏感性增加

获取原文

获取原文并翻译 | 示例

开具论文收录证明 >>

页面导航

著录项
引文网络
相似文献
相关主题

著录项

来源
《Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer》 |2017年第1期|共1页
作者
Meng Welliver; Feng Jin; Gregory Otterson; David Carbone;
展开▼
作者单位

Radiation Oncology The Ohio State University Ccc;

Radiation Oncoloy The Ohio State University;

Radiation Oncology The Ohio State University Ccc;

Internal Medicine The Ohio State University Ccc;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. P2.01-092 PRMT5 is a Poor Prognostic Marker for NSCLC and Inhibition of PRMT5 Results in Increased Lung Cancer Sensitivity to Cisplatin and Radiotherapy [J] . Meng Welliver, Feng Jin, Gregory Otterson, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2017,第1期

机译：P2.01-092 PRMT5是NSCLC的较差的预后标记，抑制PRMT5导致肺癌对顺铂和放射治疗的敏感性增加
2. Circular RNA PRMT5 confers cisplatin-resistance via miR-4458/REV3L axis in non-small-cell lung cancer [J] . Pang Jun, Ye Liwen, Zhao Dan, Cell biology international. . 2020,第12期

机译：圆形RNA PRMT5通过MIR-4458 / Rev3L轴在非小细胞肺癌中赋予顺铂抗性
3. P1.03-039 Therapeutic Inhibition of the Cancer Stem Cell Marker, ALDH1, a Promising Mechanism by Which Cisplatin Sensitivity Can Be Restored in NSCLC [J] . L. Mac Donagh, S. Gray, S. Cuffe, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2017,第11期

机译：p1.03-039癌症干细胞标志物，Aldh1的治疗性抑制，可以在NSCLC恢复顺铂敏感性的有希望的机制
4. The Tumor Infiltrating Leukocyte Cell Composition Are Significant Markers for Prognostics of Radiotherapy of Rectal Cancer as Revealed by Cell Type Deconvolution [C] . Min Zhu, Xiaolai Li, Yunjian Ge, IEEE International Conference on Big Data Computing Service and Applications . 2019

机译：肿瘤浸润白细胞的细胞组成是直肠癌放疗预后的重要标志，如细胞类型反卷积所揭示
5. Use of Palliative Radiotherapy Among Metastatic Non-small-cell Lung Cancer (NSCLC) Patients in Puerto Rico [D] . ?Quinones Avila, Valerie 2020

机译：在波多黎各的转移性非小细胞肺癌（NSCLC）患者中使用姑息放射治疗
6. LKB1/KRAS mutant lung cancers constitute a genetic subset of NSCLC with increased sensitivity to MAPK and mTOR signalling inhibition [O] . C L Mahoney, B Choudhury, H Davies, 2009

机译：LKB1 / KRAS突变型肺癌构成NSCLC的遗传子集对MAPK和mTOR信号传导抑制的敏感性增加
7. LKB1/KRAS mutant lung cancers constitute a genetic subset of NSCLC with increased sensitivity to MAPK and mTOR signalling inhibition [O] . Mahoney, C L, Choudhury, B, Davies, H, 2009

机译：LKB1 / KRAS突变型肺癌构成NSCLC的遗传子集，对MAPK和mTOR信号传导抑制的敏感性增加

P2.01-092 PRMT5 is a Poor Prognostic Marker for NSCLC and Inhibition of PRMT5 Results in Increased Lung Cancer Sensitivity to Cisplatin and Radiotherapy

著录项

引文网络

相似文献

相关主题

期刊订阅